Related Experiment Video
Updated: Jun 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients
Linda Hertlein1, Miriam Lenhard, Angela Kirschenhofer
1Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, Campus Grosshadern, Marchioninistrasse 15, Munich, Germany. Linda.hertlein@med.uni-muenchen.de
Objective:
Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited. Therefore, interest has increased in targeted therapeutics for the treatment of cervical cancer. Cetuximab, a monoclonal antibody, binds specifically to the epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor and other ligands. In cervical cancer the expression of EGFR is reported in up to 85% of the tumour cells. Therefore, Cetuximab monotherapy could be a new option in the treatment of patients with advanced cervical cancer.
Study Design:
Five patients with advanced cervical cancer were treated with Cetuximab monotherapy as third- to fifth-line therapy between 2005 and 2008 in our institution. The tumour stage at the time of diagnosis ranged between IIB and IVB. Cetuximab was applied with an initial loading dose of 400 mg/m(2) followed by a dose of 250 mg/m(2) weekly.
Results:
Only one patient (20%) had a stable disease, and the other four a progressive disease during Cetuximab monotherapy, after the RECIST criteria. Four out of five patients (80%) developed an acneiform rash as a common observed side effect of Cetuximab therapy. The median survival time from the beginning of the Cetuximab therapy was 8.6 months.
Conclusion:
No advantage could be found in the treatment with Cetuximab monotherapy in patients with advanced cervical cancer in this study. Further studies are necessary to evaluate the significance of Cetuximab in the treatment of advanced cervical cancer.
Insights
Cetuximab monotherapy showed limited efficacy in advanced cervical cancer patients, with only one achieving stable disease. Further research is needed to determine Cetuximab
Area of Science:
- Oncology
- Cancer Therapeutics
Background:
- Advanced cervical cancer has limited treatment options.
- Targeted therapies are being explored for cervical cancer treatment.
- Cetuximab targets the epidermal growth factor receptor (EGFR), which is highly expressed in cervical tumors.
Purpose of the Study:
- To evaluate the efficacy of Cetuximab monotherapy in patients with advanced cervical cancer.
- To assess Cetuximab as a potential treatment option for advanced cervical cancer.
Main Methods:
- A study involving five patients with advanced cervical cancer treated with Cetuximab monotherapy.
- Patients received Cetuximab as third- to fifth-line therapy.
- Tumor stages ranged from IIB to IVB, with specific dosage regimens for Cetuximab.
Main Results:
- Only one patient (20%) achieved stable disease; four patients (80%) experienced progressive disease.
- Acneiform rash was a common side effect in 80% of patients.
- The median survival time was 8.6 months from the start of Cetuximab therapy.
Conclusions:
- Cetuximab monotherapy did not demonstrate significant advantages in treating advanced cervical cancer in this study.
- Further clinical trials are required to fully understand the role of Cetuximab in advanced cervical cancer treatment.
Related Concept Videos
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers